Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài: WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE. | Int. J. Med. Sci. 2010 7 72 International Journal of Medical Sciences 2010 7 2 72-81 Ivyspring International Publisher. All rights reserved Research Paper WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE Miwako Narita1 H Masayoshi Masuko2 Tohri Kurasaki3 Toshiki Kitajima3 Shoko Takenouchi3 Anri Saitoh1 Norihiro Watanabe1 Tatsuo Furukawa2 Ken Toba3 Ichiro Fuse4 Yoshifusa Aizawa3 Manabu Kawakami5 Yoshihiro Oka6 Haruo Sugiyama6 and Masuhiro Takahashi1 1. Laboratory of Hematology and Oncology Graduate School of Health Sciences Niigata University Niigata Japan 2. Division of Stem Cell Transplantation Niigata University Medical and Dental General Hospital Niigata Japan 3. Division of Hematology Graduate School of Medical and Dental Sciences Niigata University Niigata Japan 4. Division of Bioscience Medical Research Center Niigata University Medical and Dental General Hospital Niigata Japan 5. Department of Medicine National Hospital Organization Osaka Minami Medical Center Osaka Japan 6. Department of Functional Diagnostic Science Osaka University Graduate School of Medicine Osaka Japan ISI Corresponding author Miwako Narita . Laboratory of Hematology and Oncology Graduate School of Health Sciences Niigata University 2-746 Asahimachi-dori Chuo-ku Niigata 951-8518 Japan. Telephone fax 81-25227-0836 email naritami@ Received Accepted Published Abstract Although tyrosine kinase inhibitors is effective for dramatically reducing CML cells it might be difficult to eradicate completely the CML stem cells. We aimed to clarify the safety and effects of WT1 peptide vaccination in combination with imatinib therapy for a CML patient. A 51 year-old male with CML in CP who showed a resistance against imatinib therapy for years began to be treated with 9mer modified-type WT1 peptides in combination with standard dose of imatinib. Although every 2-week-administration of WT1
